comparemela.com

Latest Breaking News On - Amylyx pharmaceuticals inc - Page 1 : comparemela.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Shares Sold by Avidity Partners Management LP

Avidity Partners Management LP lessened its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 96.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 64,501 shares of the company’s stock after selling 1,692,439 shares during the quarter. Avidity Partners Management […]

Switzerland
Canada
United-states
Swiss
Leerink-partnrs
Nasdaq
Swiss-national-bank
Amylyx-pharmaceuticals-stock-down
Amylyx-pharmaceuticals-inc
Janney-montgomery-scott
Amylyx-pharmaceuticals-profile
Rafferty-asset-management

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. ...

Lifshitz Law PLLC Announces Investigations of Cassava Sciences, Inc. ...
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

New-york
United-states
Joshua-lifshitz
Joshuam-lifshitz
Rhythm-technologies-inc
Nasdaq
Investigations-of-cassava-sciences-inc
News-network
Amylyx-pharmaceuticals-inc
Cassava-sciences-inc
Cassava-sciences
Xponential-fitness-inc

Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)

Analysts Offer Insights on Healthcare Companies: Cooper Co (COO), Vertex Pharmaceuticals (VRTX) and Guardant Health (GH)
businessinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from businessinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
America
Ji-nam
Castle-biosciences
Pacific-biosciences
Geoff-meacham
Integra-lifesciences
Robbie-marcus
Mineralys-therapeutics-inc
Vertex-pharmaceuticals
Cooper-co
Amylyx-pharmaceuticals-inc

Amylyx Pharmaceuticals (NASDAQ:AMLX) Given New $3.00 Price Target at Mizuho

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price objective reduced by Mizuho from $4.00 to $3.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a neutral rating on the stock. A number of other equities research analysts have also weighed in on the company. The Goldman Sachs Group […]

United-states
Canada
Gina-mazzariello
Joshuab-cohen
Robertw-baird
Qube-research-technologies-ltd
Amylyx-pharmaceuticals
Amylyx-pharmaceuticals-inc
Amylyx-pharmaceuticals-stock-performance
News-ratings-for-amylyx-pharmaceuticals-daily
Institutional-trading-of-amylyx-pharmaceuticals
Rafferty-asset-management

Amylyx Pharmaceuticals (NASDAQ:AMLX) Price Target Cut to $3.00

Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its price target decreased by Mizuho from $4.00 to $3.00 in a report issued on Tuesday, Benzinga reports. Mizuho currently has a neutral rating on the stock. A number of other research firms have also recently weighed in on AMLX. HC Wainwright reaffirmed a buy rating and issued […]

United-states
Arizona
China
Canada
Leerink-partnrs
Robertw-baird
Zurcher-kantonalbank-zurich-cantonalbank
Gina-mazzariello
Joshuab-cohen
China-universal-asset-management-co
Quest-partners
Amylyx-pharmaceuticals-stock-performance

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.